ERBB2 and breast carcinoma: Assessment of P2X5 expression using microarray data from 264 human breast cancer samples classified as luminal (A/B), ERBB2+ or basal, indicated that P2X5 is significantly upregulated in the basal subset of clinical breast cancer samples compared to all other subtypes.